



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2012

---

## **Necrotizing infundibular crystalline folliculitis: a clinicopathological study**

Denisjuk, Natalja ; Hilty, Norbert ; Pfaltz, Madeleine ; Kempf, Werner

DOI: <https://doi.org/10.1016/j.jaad.2011.05.050>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-68907>

Journal Article

Accepted Version

Originally published at:

Denisjuk, Natalja; Hilty, Norbert; Pfaltz, Madeleine; Kempf, Werner (2012). Necrotizing infundibular crystalline folliculitis: a clinicopathological study. *Journal of the American Academy of Dermatology*, 66(5):823-826.

DOI: <https://doi.org/10.1016/j.jaad.2011.05.050>

Manuscript Number: JAAD-D-10-01308R1

Title: Necrotizing infundibular crystalline folliculitis

Article Type: Dermatopathology

Keywords: Crystalline folliculitis, birefringence, acne, gram-positive bacteria, Propionibacteria, yeasts, Malassezia, Pityrosporum.

Corresponding Author: Prof. Werner Kempf, M. D.

Corresponding Author's Institution:

First Author: Natalja Denisjuk

Order of Authors: Natalja Denisjuk; Norbert Hilty, MD; Madeleine Pfaltz, MD; Werner Kempf

**Abstract:** Background: Necrotizing infundibular crystalline folliculitis (NICF) is a folliculocentric disorder associated with filamentous crystalline deposits, enclosed by parakeratotic columns within the partly necrotic follicle ostium and infundibulum. There are only very few data published about this disorder of unknown etiology.

**Objective:** To determine the clinico-pathological features and pathogenetic aspects of NICF.

**Methods:** Clinico-pathological characterization of nine patients with NICF and a second group of seven cases with coincidental findings of NICF in the vicinity of epithelial skin neoplasms.

**Results:** Clinically NICF is characterized by multiple waxy papules with predilection for the forehead (56%), neck and back. Birefringent crystalline deposits were present in the follicle ostia and enclosed by parakeratotic columns in all cases. The necrosis of follicle epithelium was found in 89% and perifollicular neutrophilic infiltrate in 22% of the biopsies. Both yeasts and gram-positive bacteria were identified within the affected follicles in 56% in the first group and in the second group in 86%.

**Limitation:** Single center retrospective study.

**Conclusions:** NICF is both a distinct entity and an epiphenomenon in the context of other disorders. In regard to the common association with yeast and gram-positive bacteria in the affected follicles, we hypothesize that NICF is pathogenetically linked to these organisms which is supported by resolution after topical or systemic antimycotic treatment.

Dear Dr. Shea

We are submitting the enclosed revised manuscript "necrotizing infundibular crystalline folliculitis" (JAAD-D-10\_01308 R1) as an original article to the Journal. We are very grateful for the comments of the reviewers. Enclosed please find the point-by-point answers to their comments. The corresponding changes in the manuscript has been highlighted by red.

Point-by-point answers to the reviewer's comments

(1) According to the comment of reviewer #1, we have now added an investigation of 9 cases of ostiofolliculitis. This investigation was mentioned in the lines 12 to 13. The results have been added in the revised manuscript in the lines 35 ff. "... and 9 cases with ostiofolliculitis were collected"; and in the lines 74 to 76: "Only few yeast spores were found in 2 cases (2 of 9; 22%) and bacteria in 4 cases (4 of 9; 44%) of ostiofolliculitis. Neither crystalline deposits nor necrosis of follicle epithelium were observed in any of these cases".

(2) Following reviewer #2, we have added the reference by Cribier et al. to the revised manuscript on line 88 "...and in 2003 by Cribier et al. [10] as a further case report." The reference has been added to the references: Cribier BJ, Boehm N, Heid E, Grosshans E. Pathogenesis: Crystals in association with degenerated corneocytes in plugs of infundibula induce a distinctive papular eruption on the face. *Dermatopathology: Practical and Conceptual* 2003; 9 (2); published online at <http://www.derm101.com>.

(3) The finding of similar findings has been added and discussed in the revised manuscript in lines 137 to 139 with “Additionally the crystalline birefringent structures observed also in 3,5 % of 200 epidermal cysts were supposed by Cribier et al. to be keratinous fundamentally [10].”

(4) As proposed by the reviewer, we have added a photomicrograph as a figure 4 depicting coincidental NICF changes in close vicinity to an actinic keratosis.

We hope that the revised manuscripts fulfills the requirements and high standard for publication in the Journal. We very much appreciate your evaluation of our manuscript.

Yours sincerely,

Werner Kempf

1 **Necrotizing infundibular crystalline folliculitis: A clinical-**  
2 **pathological study**

3 Natalja Denisjuk<sup>1</sup>, MD, Norbert Hilty<sup>2</sup>, MD, Madeleine Pfaltz<sup>1</sup>, MD, Werner Kempf<sup>1</sup>, MD  
4 Zürich, Switzerland and Schaan, Liechtenstein

5 From the Kempf and Pfaltz, Histological Diagnostics, CH-8042 Zürich, Switzerland<sup>1</sup> and  
6 Dermatology Practice, FL-9494 Schaan, Liechtenstein<sup>2</sup>

7 **Corresponding author:** Werner Kempf, MD, Kempf and Pfaltz, Histological Diagnostics,  
8 CH-8042 Zürich, Switzerland, Phone: +41-44-233 33 77, Fax: +41-44-233 33 78

9 Email: [kempf@kempf-pfaltz.ch](mailto:kempf@kempf-pfaltz.ch)

10 Funding sources: None.

11 Conflicts of interest: The authors have no conflict of interest to declare.

12 Prior presentation: It was presented as a poster at the annual meeting of the Swiss Society of  
13 Dermatology in 2010

14 Text word count: 2401.

15 Number of references: 10.

16 Number of tables: 2.

17 Number of Figures: 4.

- Necrotizing infundibular crystalline folliculitis is characterized by waxy lesions and histologically by folliculocentric filamentous negative birefringent crystalline deposits.
- The median age of patients was 51 years and more commonly forehead, neck and back involvement.
- Yeast and gram-positive bacteria were identified in the majority of cases.
- Topical or systemic antimycotics may be useful in the treatment of this disorder.

## 1 Introduction

2 The microscopical findings of necrotizing infundibular crystalline folliculitis (NICF) were  
3 first described by Lucke[1] and coworkers in 1999 as transepidermal elimination of urate-like  
4 crystals followed by the case report by Kossard[2] et al. in 2001 under the term of NICF.

5 This disorder is characterized clinically by sharply demarcated waxy papules and  
6 histologically by distinctive filamentous material within the partly necrotic hair follicle  
7 ostium and infundibulum. In the cases described by Lucke and coworkers negative  
8 birefringent needle-shaped crystals within the filamentous material were identified. Various  
9 hypotheses for the development of NICF have been proposed[1][2]. The pathogenesis and the  
10 clinicopathological features including its course remain to be elucidated. We therefore studied  
11 9 patients with histologically proven NICF, a series of biopsies, in which similar histological  
12 findings were observed coincidentally with other skin disorders and a series of biopsies with  
13 ostiofolliculitis.

14

15

16

17

18

19

20

21

22

23

24

25

26

27

## 28 **Materials and Methods**

29 All lesions diagnosed as NICF between 2006 and 2010 were retrieved from the files of our  
30 dermatopathology laboratory. A total of 9 cases with the diagnosis of NICF were identified.

31 Data from these cases were compiled and analyzed for age **of the patient** at diagnosis, gender,  
32 localization and clinical as well as histological features of the lesions. Data on therapy and its  
33 outcome were obtained from the treating dermatologists. In addition to the 9 patients with  
34 NICF, 7 cases with coincidental findings of NICF associated with different epithelial skin  
35 neoplasms **and 9 cases with ostiofolliculitis were collected.**

36 All biopsies were formalin-fixed paraffin-embedded. The cases were routinely stained for  
37 hematoxylin and eosin, periodic-acid-Schiff and Brown-Brenn-Gram to identify fungi and  
38 bacteria, respectively. In addition, all biopsies were analyzed by polarizing light microscopy.

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54



## 55 Results

56 Results are summarized in Table 1. There were 4 male and 5 female patients, aged between  
57 20 and 72 years (median age = 51 years). All but three lesions developed on the forehead  
58 (5 out of 9, 56%) (Fig. 1), followed by back (2 out of 9; 22%), neck and nose in equal  
59 proportions (1 out of 9; 11%). Lesions generally consisted clinically of waxy erythematous  
60 papules.

61 All cases of NICF showed birefringent crystalline deposits within the follicle ostia enclosed  
62 by parakeratotic columns (Fig. 2). The necrosis of follicle epithelium was found in 8 out of 9  
63 cases (89%). Perifollicular neutrophil granulocytes infiltrate was present in 2 out of 9 cases  
64 (22%). In all cases (9 out of 9; 100%) the filamentous material contained birefringent urate-  
65 like crystal structures revealed by polarizing light (Fig. 3). Yeasts and gram-positive bacteria  
66 were detected within the affected follicles in equal proportions in 5 cases (56%).

67  
68 The constant finding in all cases with coincidental findings of NICF was crystalline deposits  
69 within the follicle ostium enclosed by parakeratotic columns (Fig. 4). Neither the necrosis of  
70 follicle epithelium nor perifollicular neutrophils could be detected in any of these cases.

71 Yeasts and gram-positive bacteria were present within the affected follicles in equal  
72 proportions in the majority of cases with coincidental findings of NICF (n=6, 86%).

73  
74 Only few yeast spores were found in 2 cases (2 of 9; 22%) and bacteria in 4 cases (4 of 9;  
75 44%) of ostiofolliculitis. Neither crystalline deposits nor necrosis of follicle epithelium were  
76 observed in any of these cases.

77

78

79

80

81

## 82 Discussion

83 The designation of NICF was introduced by Kossard et al in 2001[2] to describe a  
84 folliculocentric umbilicated crater filled mostly by filamentous material surrounded by a  
85 parakeratotic rim and lined by partly necrotic hair follicle epithelium. Similar histological  
86 findings with birefringent crystalline urate-like structures within the filamentous material had  
87 been described before by Lucke et al[1] as transepidermal elimination of urate-like crystals  
88 and in 2003 by Cribier et al. [10] as a further case report.

89 Our study is the first analyzing a series of patients with NICF. In our series, both genders are  
90 equally affected by NICF. Most patients are in the 5th decade with a broad range of age at  
91 diagnosis. The head and neck area, particularly the forehead, is the predilection site involved  
92 in 78% of the patients, followed by the back. NICF shares therefore the predilection sites of  
93 acne. The clinical manifestation of NICF with waxy papules, however, is different from acne.

94  
95 Our series show all histological hallmarks in accordance with the three prior reports. The  
96 pathognomic filamentous material containing birefringent urate-like crystals in all cases,  
97 however, was located mostly in the ostia in the hair follicles and rarely in the infundibular  
98 region (1out of 9 cases; 11%). Thus we propose to modify the term necrotizing infundibular  
99 crystalline folliculitis to necrotizing ostial crystalline folliculitis. Focal necrosis of the hair  
100 follicle epithelium was found in about 90% of the biopsies and column-like  
101 hyperparakeratosis surrounding the filamentous material was observed in all biopsies  
102 rendering these features to pathognomic findings. An inflammatory infiltrate was present in  
103 more than half of the biopsies, but neutrophils admixed to the infiltrate were not a consisting  
104 feature as they were found in only 22% of the biopsies.

105  
106 Remarkably, yeasts (with the morphology Malassezia) as well as gram-positive bacteria  
107 (corresponding to Propionibacterium acnes) were detectable in approximately in 56 % of  
108 cases with the NICF and in 86 % of the biopsies, in which NICF was a coincidental finding

109 accompanying other disorders. Similar clinical picture with small whitish follicular papules  
110 associated with *Malassezia* spp. had been referred as Pityriasis versicolor papulosa by Male in  
111 1978[9]. Unlike NICF only few yeast spores were found in 22 % and bacteria in 44% of  
112 ostiofolliculitis cases.

113

114 Two principal pathways for the etiopathogenesis of NICF have been proposed. Kossard and  
115 coworkers hypothesized that either physical or chemical injury or bacteria and *Malassezia*  
116 yeasts in the infundibulum of follicles may induce the crystalline structures[2]. Montagna[4]  
117 reported in 1963 about polarizable crystals of sebaceous lipids and recognized them as esters  
118 of cholesterol. These crystals resist HE-related solvents in histological preparations and  
119 water-based potassium hydroxide solution in their fresh preparations[5]. These features rule  
120 out that the crystals in NICF consist only of pure cholesterol and urate crystals.

121 Different cell types of the epidermis with the enzymatic potential for cholesterol esterification  
122 were established by Freinkel and Aso[6]. Gonzalez-Serva et al.[5] 2004 demonstrated  
123 polarizable crystals in vast majority of closed acne comedones in their study. The authors  
124 suggested that crystallization of sebum is a common event during comedogenesis and crystal  
125 formation increase the cohesion of filamentous material within the comedo. Increased steryl  
126 ester levels were found in lipids extracted from comedones, compared to lipids from skin  
127 surface wipings, probably because of concentrated bacterial proliferation and cholesterol  
128 esterification within the comedones [7]. Puhvel[8] demonstrated that *Propionibacteria* are also  
129 able to esterify cholesterol. Furthermore the lipases of *Propionibacteria* hydrolyze di- and  
130 triglycerides to free fatty acids and glycerol. The esterification of cholesterol is often  
131 increased by *Propionobacterium acnes* within the comedones. *Malassezia* spp. are lipid  
132 dependent yeasts and require an external source of lipid e. g. free fatty acids and triglycerides  
133 produced by sebaceous glands. *Malassezia* species produce an enzyme with lipoxygenase  
134 activity, as demonstrated by its ability to oxidize free and esterified unsaturated fatty acids,  
135 squalene and cholesterol derived in part from the decomposition of corneocytes[9].

136 Catterall et al. 1978 referred previously accumulation of amorphous material between the  
137 squamae as a result of destruction of tonofilaments of corneocytes by *Malassezia* spp.  
138 penetrating Str. corneum. Kossard et al. 2001[2] detected disrupted tonofilaments within the  
139 amorphous material of NICF by electron microscopy. **Additionally the crystalline birefringent**  
140 **structures observed also in 3,5 % of 200 epidermal cysts were supposed by Cribier et al. to be**  
141 **keratinous fundamentally [10].**

142 In conclusion, our study demonstrates that NICF represents a distinct nosologic entity with  
143 characteristic clinical and histological features. Similar findings, however, may be observed  
144 as an incidental histologic finding in the context of other skin disorders, particularly in close  
145 vicinity to epithelial skin neoplasms. The latter phenomenon could be termed secondary  
146 NICF. We hypothesize that either sebum cumulate and crystallize thereby serving as nutrient  
147 medium for yeast and bacteria, or alternatively *Propionibacteria* and *Malassezia* spp. destruct  
148 tonofilaments and degrade lipids which results in accumulation of filamentous material with  
149 birefringent crystals within the hair follicle ostia and infundibula. The increasing amount of  
150 the filamentous material results in rupture of the follicular epithelium with subsequent  
151 inflammatory reaction. The clinical response of NICF to topical or systemic antimycotic  
152 treatment underlines the pathogenetic role of microorganisms in NICF.

## 1   **References**

- 2   1.    Lucke TW, Fallowfield ME, Evans A, Lowe JG, MacKie RM. Transepidermal  
3       elimination of urate-like crystals: a new perforating disorder? *Br J Dermatol*  
4       1999;141:310-4.
- 5   2.    Kossard S, Scurry J, Killingsworth M. Necrotizing infundibular crystalline folliculitis.  
6       *Br J Dermatol* 2001;145:165-8.
- 7   3.    Montagna W., The sebaceous glands; proceedings of the Brown University  
8       symposium on the biology of skin. In: *Advances in biology of skin*. Vol. 4. Oxford:  
9       Pergamon Press; 1963, p. 260.
- 10  4.    González-Serva A, Kroumpouzou G. Demonstration of polarizable crystals in fresh  
11       comedonal extracts: sebum crystallizes. *Acta Derm Venereol* 2004;84:418-21.
- 12  5.    Freinkel RK, Aso K. Esterification of cholesterol by epidermis. *Biochim Biophys Acta*  
13       1971;239:98-102.
- 14  6.    Nicolaidis N, Ansari MN, Fu HC, Lindsay DG. Lipid composition on comedones  
15       compared with that of human skin surface in acne patients. *J Invest Dermatol* 1970;  
16       54:487-95.
- 17  7.    Puhvel SM. Esterification of (4-<sup>14</sup>C)cholesterol by cutaneous bacteria  
18       (*Staphylococcus epidermidis*, *Propionibacterium acnes*, and *Propionibacterium*  
19       *granulosum*). *J Invest Dermatol* 1975;64:397-400.
- 20  8.    Nazzaro-Porro M, Passi S, Picardo M, Mercantini R, Breathnach AS. Lipoxygenase  
21       activity of *Pityrosporum* in vitro and in vivo. *J Invest Dermatol* 1986;87:108-12.
- 22  9.    Male O. Pilzkrankheiten. In: Doerr W, Seifert G, Uehlinger E, editors. *Spezielle*  
23       *pathologische Anatomie*. Band 7. *Histopathologie der Haut*. Berlin, Heidelberg, New  
24       York: Springer; 1978, p. 88.

- 25 10. Cribier BJ, Boehm N, Heid E, Grosshans E. Pathogenesis: Crystals in association with  
26 degenerated corneocytes in plugs of infundibula induce a distinctive papular eruption  
27 on the face. *Dermatopathology: Practical and Conceptual* 2003; 9 (2); published  
28 online at <http://www.derm101.com>.

29

30

## \*Abbreviations (Revision)

- 1 Abbreviations used:
- 2 NICF: Necrotizing infundibular crystalline folliculitis

**Table 1** Table I. Clinical and histological summary of patients with NICF

Case	Age and gender	Clinical information	Location	Malassezia	Bacteria	Necrosis	Parakeratosis	Neutrophils	Birefringence
1	51 m	Waxy papules, lichenoid exanthema, Amyloid	Forehead	No	No	Yes	Yes	No	Yes
2	72 w	Atopic dermatitis, photoallergic reaction	Scapula	Yes	No	Yes	Yes	No	Yes
3	57 m	Follicular hyperkeratosis, spicules like at multiple myeloma	Forehead	n/a	n/a	Yes	Yes	No	Yes
4	34 w	Pustules, atopic dermatitis, dd pityrosporum, impetigo, Darier	Neck	Yes	No	n/a	Yes	No	Yes
5	20 w	Folliculitis, dense keratotic papules, partly molluscoid	Back	Yes	Yes	Yes	Yes	Yes	Yes
6	58 m	rosacea, molluscoid papules	Forehead	Yes	No	Yes	Yes	No	Yes
7	64 w	folliculitis	Forehead	Yes	Yes	Yes	Yes	No	Yes
8	40 m	Rosacea, dd lupus erythematosus	Nose	Yes	Yes	Yes	Yes	Yes	Yes
9	48 w	Acne, rosacea, folliculitis, lupus	Forehead	No	Yes	Yes	Yes	No	Yes

n/a, not applicable



**Table 2** Table II. Clinical and histological summary of patients with coincidentally findings of NICF


Case	Age and gender	Clinical information	Location	Malassezia	Bacteria	Necrosis	Parakeratosis	Neutrophils	Birefringence
1	73 w	Actinic keratosis	Nose	Yes	Yes	No	Yes	No	Yes
2	46 m	Precancerosis, basal cell carcinoma	Nose	Yes	Yes	n/a	Yes	No	Yes
3	53 m	Seborrhoic keratosis, squamous cell cacinoma	Chin	Yes	Yes	No	Yes	No	Yes
4	70 m	Basal cell carcinoma	Forehead	No	Yes	No	Yes	No	Yes
5	82 m	Basal cell carcinoma	Thorax	Yes	Yes	No	Yes	Yes	Yes
6	66 m	Actinic keratosis	Temple	Yes	No	No	Yes	No	Yes
7	73 m	Actinic keratosis	Forehead	Yes	Yes	No	Yes	No	Yes

n/a, not applicable

**Figure 1**  
[Click here to download high resolution image](#)



Figure 2  
[Click here to download high resolution image](#)



**Figure 3**  
[Click here to download high resolution image](#)





Figure 4  
[Click here to download high resolution image](#)



- 1 Fig 1. Waxy erythematous papules on the forehead.

## Figure Legend 2

- 1 Fig 2. Filamentous deposits, enclosed by parakeratotic columns within the partly necrotic
- 2 follicle ostium (Hematoxylin-eosin stain; original magnification: x 10).

### Figure Legend 3

- 1 Fig 3. Filamentous negative birefringent crystalline deposits within the follicle ostium
- 2 (Hematoxylin-eosin stain; original magnification: x 4).



## Figure Legend 4

- 1 Fig 4. Coincidental NICF changes in close vicinity to an actinic keratosis
- 2 (Hematoxylin-eosin stain; original magnification: x 10).

Herr  
Johannes Kaiser  
Platta 39  
9488 Schellenberg

Zürich, 25.08.2010 (mr)

To whom it may concern

**Patienteneinverständniserklärung**  
**Patient informed consent**

Ich erkläre mich mit der Publikation des klinischen Bildes meiner Hautveränderungen einverstanden.

I agree with the publication of the clinical image demonstrating my skin lesions.



.....  
Unterschrift  
Signature

### Authorship statement

All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication before its appearance in the *Journal of the American Academy of Dermatology*. If this study has been or will be presented at a national meeting, indicate the appropriate information on the title page.

**Acknowledgment:** All persons who have made substantial contributions to the work reported in the manuscript (including writing and editing assistance), but who are not authors, are named in the Acknowledgment and have given me (us) their written permission to be named. If I (we) do not include an acknowledgment, that means I (we) have not received substantial contributions from nonauthors.

Each author's name must be typed underneath the signature.

Author(s) signature(s)

Natalja Duvitski / ND

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Date signed

Sept. 9/2010

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

**Authorship statement**

All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication before its appearance in the *Journal of the American Academy of Dermatology*. If this study has been or will be presented at a national meeting, indicate the appropriate information on the title page.

**Acknowledgment:** All persons who have made substantial contributions to the work reported in the manuscript (including writing and editing assistance), but who are not authors, are named in the Acknowledgment and have given me (us) their written permission to be named. If I (we) do not include an acknowledgment, that means I (we) have not received substantial contributions from nonauthors.

Each author's name must be typed underneath the signature.

Author(s) signature(s)

  
\_\_\_\_\_

WERNER KEMPF

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Date signed

  
\_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

### Authorship statement

All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication before its appearance in the *Journal of the American Academy of Dermatology*. If this study has been or will be presented at a national meeting, indicate the appropriate information on the title page.

**Acknowledgment:** All persons who have made substantial contributions to the work reported in the manuscript (including writing and editing assistance), but who are not authors, are named in the Acknowledgment and have given me (us) their written permission to be named. If I (we) do not include an acknowledgment, that means I (we) have not received substantial contributions from nonauthors.

Each author's name must be typed underneath the signature.

Author(s) signature(s)

M. Pfaltz

---

---

---

---

---

---

---

Date signed

Sept. 9/2010

---

---

---

---


### Authorship statement

All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication before its appearance in the *Journal of the American Academy of Dermatology*. If this study has been or will be presented at a national meeting, indicate the appropriate information on the title page.

**Acknowledgment:** All persons who have made substantial contributions to the work reported in the manuscript (including writing and editing assistance), but who are not authors, are named in the Acknowledgment and have given me (us) their written permission to be named. If I (we) do not include an acknowledgment, that means I (we) have not received substantial contributions from nonauthors.

Each author's name must be typed underneath the signature.

Author(s) signature(s)



MD Norbert Hilly

Date signed

2. September 2010


### Authorship statement

All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication before its appearance in the *Journal of the American Academy of Dermatology*. If this study has been or will be presented at a national meeting, indicate the appropriate information on the title page.

**Acknowledgment:** All persons who have made substantial contributions to the work reported in the manuscript (including writing and editing assistance), but who are not authors, are named in the Acknowledgment and have given me (us) their written permission to be named. If I (we) do not include an acknowledgment, that means I (we) have not received substantial contributions from nonauthors.

Each author's name must be typed underneath the signature.

Author(s) signature(s)



MD Norbert Hilly

Date signed

2. September 2010



# JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

## REQUIRED SUBMISSION FORM AND CHECKLIST FOR AUTHORS

(Photocopy this page, complete all applicable sections, and submit with manuscript)

Corresponding Author: Werner Kempf, MD  
 Phone No: 441-442-3337 Fax No: 441-442-3337 E-mail: kempf@kempf-pfalz.ch

- Cover letter:
  - Title, brief description of manuscript and its significance to dermatologists
  - Suggested section
  - Explanation of any conflicts of interest
  - Possible reviewers
  - Signed copyright transfer statement (on or off-line submission)
- Signed authorship statement from each author (on or off-line submission)
- Signed conflict of interest statement from each author (on or off-line submission)
- Copy of Institutional Review Board approval for clinical research trials (on-line submission) } *not applicable*
- CONSORT checklist for randomized trials (on-line submission) }
- Manuscript double-spaced with each section beginning on a new page
- Number the pages in the upper right corner, beginning with the title page
- Submission is line numbered
- Title page
  - Title of article
  - Full name(s), academic degrees, and academic, institutional, and relevant corporate affiliations of author(s)
  - All writers and contributors who participated in the preparation of the manuscript are listed as authors, (see author attestation form)
  - Name, address, business telephone and fax numbers, and E-mail address of author to whom correspondence should be sent. Do not designate trainees or medical students for this purpose.
  - Statement of all funding sources for this work (if none, please state)
  - Publishable disclosure statement of potential conflicts of interest for each author. If none, please state:  
The authors have no conflict of interest to declare
  - Statement on prior presentation
  - Reprint request line
  - Text word count, number of references, tables, and figures
- Abstract (double-spaced), including limitations section, starting on a separate sheet (when required by article type)
- References (double-spaced), starting on a separate sheet
- Tables (double-spaced), each on a separate sheet
- Figure legends (double-spaced), starting on a separate sheet
- Abbreviation and acronym list on separate sheet
- Patient consent letters (photographic and informed consent) (on or off-line submission)
- Permission to reproduce material published previously (on or off-line submission)
- Contents of the manuscript have not been previously published and are not currently submitted elsewhere
- All human and animal studies are approved by an Institutional Review Board. *not applicable to this study.*
- I accept responsibility for the scientific integrity of the work described in this manuscript.
- All listed authors have seen and approved of the manuscript and will sign off on any subsequent manuscript revisions.

Signature of corresponding author who verifies that above is correct  


Sept. 9/2010  
Date



### Conflict of interest statement

I (we) certify that any affiliations with or involvement (eg, honoraria; education grants; speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript are disclosed in the submission letter and on the title page. If none, state "none" below.

Each author's name must be typed underneath the signature.

Author(s) signature(s)

*Natalya Gurtjiv / D*

---

---

---

---

---

Date signed

*Apr. 9/2010*

---

---

---

---

---

**Conflict of interest statement**

I (we) certify that any affiliations with or involvement (eg, honoraria; education grants; speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript are disclosed in the submission letter and on the title page. If none, state "none" below.

Each author's name must be typed underneath the signature.

Author(s) signature(s)

  
\_\_\_\_\_  
WERNER KEMPF  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Date signed

Sept. 9/2010  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**Conflict of interest statement**

I (we) certify that any affiliations with or involvement (eg, honoraria; education grants; speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript are disclosed in the submission letter and on the title page. If none, state "none" below.

Each author's name must be typed underneath the signature.

Author(s) signature(s)

*M. Pfaltz*

---

---

---

---

---

---

Date signed

*Sept. 9/2010*

---

---

---

---

---

---

**Conflict of interest statement**

I (we) certify that any affiliations with or involvement (eg. honoraria, education grants; speakers' bureaus, membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript are disclosed in the submission letter and on the title page. If none, state "none" below.

Each author's name must be typed underneath the signature.

„none“

Author(s) signature(s)

  
MD Norbert Hilly

Date signed

2. September 2010

### Transfer of copyright

I (we), the undersigned author(s), transfer all copyright ownership of the manuscript referenced above to the American Academy of Dermatology, in the event the work is published. I (we) warrant that the article is original, does not infringe upon any copyright or other proprietary right of any third party, is not under consideration by another journal, and has not been published previously. I (we) have reviewed and approve the submitted version of the manuscript and agree to its publication in the *Journal of the American Academy of Dermatology*.

Each author's name must be typed underneath the signature.

Author(s) signature(s)

Natalja Demitrova, MD  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Date signed

Apr. 9/2010  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

US Federal Employees: If you are an employee of the US federal government, please sign the following statement: I was an employee of the US federal government when this work was conducted and prepared for publication; therefore the work lies within the public domain and is not subject to the Copyright Act. Ownership of copyright cannot be transferred. **If you are not a government employee, do not sign.**

Each author's name must be typed underneath the signature.

Author(s) signature(s)

\_\_\_\_\_

### Transfer of copyright


I (we), the undersigned author(s), transfer all copyright ownership of the manuscript referenced above to the American Academy of Dermatology, in the event the work is published. I (we) warrant that the article is original, does not infringe upon any copyright or other proprietary right of any third party, is not under consideration by another journal, and has not been published previously. I (we) have reviewed and approve the submitted version of the manuscript and agree to its publication in the *Journal of the American Academy of Dermatology*.

Each author's name must be typed underneath the signature.

Author(s) signature(s)

  
\_\_\_\_\_  
WERNER KEMPF  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Date signed

  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

US Federal Employees: If you are an employee of the US federal government, please sign the following statement: I was an employee of the US federal government when this work was conducted and prepared for publication; therefore the work lies within the public domain and is not subject to the Copyright Act. Ownership of copyright cannot be transferred. **If you are not a government employee, do not sign.**

Each author's name must be typed underneath the signature.

Author(s) signature(s)

\_\_\_\_\_

### Transfer of copyright

I (we), the undersigned author(s), transfer all copyright ownership of the manuscript referenced above to the American Academy of Dermatology, in the event the work is published. I (we) warrant that the article is original, does not infringe upon any copyright or other proprietary right of any third party, is not under consideration by another journal, and has not been published previously. I (we) have reviewed and approve the submitted version of the manuscript and agree to its publication in the *Journal of the American Academy of Dermatology*.

Each author's name must be typed underneath the signature.

Author(s) signature(s)

*H. Pfaltz*

---

---

---

---

---

---

---

Date signed

*Sept. 9/2010*

---

---

---

---

---

---

---

**US Federal Employees:** If you are an employee of the US federal government, please sign the following statement: I was an employee of the US federal government when this work was conducted and prepared for publication; therefore the work lies within the public domain and is not subject to the Copyright Act. Ownership of copyright cannot be transferred. **If you are not a government employee, do not sign.**

Each author's name must be typed underneath the signature.

Author(s) signature(s)

---

### Transfer of copyright

I (we), the undersigned author(s), transfer all copyright ownership of the manuscript referenced above to the American Academy of Dermatology, in the event the work is published. I (we) warrant that the article is original, does not infringe upon any copyright or other proprietary right of any third party, is not under consideration by another journal, and has not been published previously. I (we) have reviewed and approve the submitted version of the manuscript and agree to its publication in the *Journal of the American Academy of Dermatology*.

Each author's name must be typed underneath the signature.

Author(s) signature(s)



MD Norbert Hilly

Date signed

2. September 2010

---

US Federal Employees: If you are an employee of the US federal government, please sign the following statement: I was an employee of the US federal government when this work was conducted and prepared for publication; therefore the work lies within the public domain and is not subject to the Copyright Act. Ownership of copyright cannot be transferred. If you are *not* a government employee, do not sign.

Each author's name must be typed underneath the signature.

Author(s) signature(s)